M Rizell, R Hultborn, P Bernhardt, J Svensson, M Sternby Eilard, O ...
M Rizell, R Hultborn, P Bernhardt, J Svensson, M Sternby Eilard, O ...
M Rizell, R Hultborn, P Bernhardt, J Svensson, M Sternby Eilard, O ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table 1b. Continued. Hepatocellular carcinoma<br />
Outcome: Tumour response<br />
Study<br />
Inarrairaegui<br />
Keppke<br />
Kooby<br />
Kulik<br />
Lau<br />
Salem<br />
Salem<br />
Young<br />
Publication<br />
year<br />
Design Number of<br />
patients<br />
Tumor<br />
evaluation<br />
TTP<br />
(months)<br />
CR (%) PR (%) SD<br />
(%)<br />
2010 Case series 50 RECIST - - 8 70 22 -<br />
2007 Case series 42 RECIST<br />
WHO<br />
Necrosis<br />
2009 Retrospective<br />
controlled?<br />
cohort<br />
n= 44 TACE<br />
n= 27 90 Y-RE<br />
Combined<br />
2008 Case series 108 WHO<br />
EASL<br />
3.9<br />
4<br />
1<br />
1<br />
RECIST -<br />
-<br />
1998 Case series 71 ”WHO” - - 26.7 - - -<br />
2009 Prospective<br />
cohort<br />
2005 Prospective<br />
cohort<br />
2007 Retrospective<br />
cohort<br />
273<br />
WHO<br />
EASL<br />
43 WHO<br />
EASL<br />
-<br />
-<br />
7.9<br />
-<br />
-<br />
-<br />
-<br />
-<br />
-<br />
-<br />
2<br />
0<br />
-<br />
-<br />
-<br />
23<br />
-<br />
-<br />
23*<br />
26*<br />
57*<br />
59*<br />
4<br />
11<br />
42*<br />
70*<br />
42*<br />
34<br />
47*<br />
79*<br />
54<br />
52<br />
-<br />
-<br />
36<br />
41<br />
-<br />
-<br />
-<br />
-<br />
-<br />
-<br />
PD<br />
(%)<br />
-<br />
-<br />
-<br />
-<br />
36<br />
33<br />
-<br />
-<br />
-<br />
-<br />
-<br />
-<br />
Quality<br />
of study<br />
41 18,1*** - - - -<br />
TTP = time to progression, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease,<br />
AFP = alfa-fetoprotein, WHO = WHO tumor response criteria<br />
*CR+PR<br />
-<br />
-<br />
-<br />
-
Change language